Generic placeholder image

CNS & Neurological Disorders - Drug Targets


ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Homocysteine in Neurological Disease: A Marker or a Cause?

Author(s): Suruchi Khanna, Puneet Kapoor, K. K. Pillai and Divya Vohora

Volume 10, Issue 3, 2011

Page: [361 - 369] Pages: 9

DOI: 10.2174/187152711794653797

Price: $65


Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.

Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy